Ethris Receives €10 Million EU4Health Grant to Support Clinical Development and Expand Antiviral Applications of Lead mRNA Candidate ETH47
'The EU4Health grant is a significant validation of ETH47's pioneering approach and its potential to offer a paradigm shift in the treatment and prevention of respiratory and broader systemic infections,' said Dr. Carsten Rudolph, CEO of Ethris. 'ETH47's ability to act at virus entry sites, combined with its room-temperature stability and potential synergy with existing antivirals, positions it as a differentiated and scalable solution for pandemic preparedness. The funding enables us to advance ETH47's clinical development and explore its wider applications beyond respiratory conditions, to address additional critical unmet needs in high-risk populations.'
The NoVir study will run from May 1, 2025, to April 31, 2027 and will include the following projects:
A clinical rhinovirus challenge study in asthmatic and chronic obstructive pulmonary disease (COPD) patients, populations at high risk for severe viral infections.
A clinical study in healthy volunteers infected with influenza to assess ETH47's antiviral efficacy.
Preclinical research exploring ETH47's protective effects against paramyxoviruses, orthomyxoviruses, coronaviridae, and bunyaviruses, including those responsible for viral hemorrhagic fevers (VHFs).
Investigation into ETH47's impact on intravaginal, ocular, and systemic infections, through multiple routes of administration, expanding its potential use beyond respiratory illnesses.
Evaluation of ETH47's ability to enhance the efficacy of existing antiviral treatments through synergistic effects.
NoVir includes collaborations with the Technical University of Munich (TUM) and Aarhus University for the preclinical research of ETH47's protective effect against different virus classes and via different infection routes. The universities' research is driven by their leading virology laboratories, which empower the project with expertise in virus systems and their replication, as well as with their established cell and animal models.
The EU4Health programme was established in response to the COVID-19 pandemic and is a European Union initiative aimed at strengthening Europe's healthcare systems and improving preparedness for future health crises. With a budget of €4.4 billion, it focuses on enhancing health promotion, disease prevention, crisis response, and healthcare access. The programme supports projects addressing long-term health challenges and contributes to the creation of a healthier European Union.
About ETH47
ETH47 is Ethris' first-in-class mRNA-based product candidate encoding interferon lambda (IFNλ) that was developed using the company's Stabilized Non-Immunogenic mRNA (SNIM ® RNA) platform, and uniquely designed to be administered locally to the respiratory tract through inhalation or nasal spray using Ethris' proprietary Stabilized NanoParticle (SNaP ®) LNP platform. ETH47 is meant to induce a mucosal innate immune defense response at virus entry sites as well as inhibit viral replication. ETH47's versatile, virus- and mutation-independent mode of action has the potential to broadly address seasonal and emerging respiratory virus infections, including virus-driven exacerbation of chronic respiratory diseases such as asthma.
About Ethris
Ethris, a clinical-stage biotechnology company, has paved a new path from genes to therapeutic proteins, using its proprietary RNA and lipidoid nanoparticle technology platform to discover, design and develop innovative therapies. With more than a decade as an mRNA pioneer, Ethris is a global leader in delivering stabilized mRNAs directly to the respiratory system via optimised formulation and nebulisation technologies. The company is rapidly advancing its mRNA pipeline of immuno-modulation, protein replacement therapies, and differentiated vaccines, with the ultimate goal of improving patients' lives.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Sun Nuclear to Highlight New Quality Management Solutions at 2025 AAPM Annual Meeting
MELBOURNE, Fla.--(BUSINESS WIRE)-- Sun Nuclear, a Mirion Medical company, will present significant additions to its comprehensive portfolio of Radiation Therapy Quality Management solutions at the 2025 American Association of Physicists in Medicine (AAPM) Annual Meeting, taking place July 27-29, in Washington, D.C. Attendees are invited to explore new software and hardware innovations designed to help elevate treatment quality, streamline workflows, and support safer care. Premiering at AAPM 2025 AdaptCHECK™ Software: AdaptCHECK is a groundbreaking quality assurance (QA) solution for adaptive therapy, enabling fast, patient-specific QA for Varian Medical Systems ® Ethos™ Therapy. Built on the SunCHECK ® Patient workflow, AdaptCHECK supports secondary dose calculations for pre-treatment QA, plan-of-the-day calculations for real-time adjustments based on patient anatomy, and quick plan re-calculations to keep treatments on track. Plan AI™ Software: Plan AI* is an AI-powered treatment planning assistant from Oncospace, now part of Sun Nuclear. The application saves time and drives continuous improvement in plan quality by providing predictive, patient-specific insights on achievable goals before planning begins. It further saves time by streamlining communication and accelerating decision-making. SunSILICON™ Detectors: Expanding the Sun Nuclear detector portfolio, SunSILICON detectors mark an intelligent evolution from the widely adopted EDGE Detector™. These precision-engineered silicon diodes are optimized for advanced relative photon and electron dosimetry, designed for SRS and SBRT, and are compatible with the cylindrical SunSCAN™ 3D water phantom. The SunSILICON model is ideal for very small photon fields and electron dosimetry. The shielded SunSILICON P model is optimized for small to large photon fields. evrCAM™ Cameras: A radiation-tolerant pan-tilt-zoom camera, evrCAM offers superior lifetime and low-light visibility, supporting reliable monitoring in radiation environments, efficient clinical workflows and enhanced patient safety. evrCAM is designed for seamless integration into treatment rooms regardless of linac type – providing clinicians with clear video for enhanced patient observation by eliminating pixelated and damaged images. Additional featured solutions include: the latest version of the SunCHECK Platform for centralized, standardized Quality Management; SciMoCa™ for Monte Carlo-based independent verification of online adaptive secondary dose calculations from Elekta ® Unity™ systems; and Gateway™, a patient data conversion solution for Pinnacle™ treatment planning. In-Booth Education and Demonstrations Throughout AAPM 2025, Sun Nuclear will host a series of presentations and hands-on demonstrations in booth 5000. Topics will span AI-powered planning, adaptive QA workflows, detector technology, and clinical use cases—delivered by both internal experts and leading clinical physicists from across the field. 'We are excited to join the medical physics community at AAPM this year, and to present a range of meaningful advancements that reflect our commitment to smarter, safer radiation therapy," said Luis Rivera, President of Sun Nuclear and Executive Vice President of Mirion Medical. "From AI-powered planning tools and adaptive-focused QA to precision detectors and robust monitoring solutions, our expanded portfolio is aimed at helping clinicians drive efficiency, elevate care, and prepare for the future of patient-centric treatment.' To learn more, visit * Plan AI software for prostate and head and neck, thoracic, abdomen, and pelvis radiotherapy is FDA 510(k) cleared, and for sale in the United States only. About Sun Nuclear Sun Nuclear is part of Mirion Medical, a group of healthcare-focused brands within Mirion, providing innovative solutions for Radiation Therapy and Diagnostic Imaging. More than 6,000 cancer centers worldwide rely on us for independent, integrated Quality Management. With a focus on ongoing support, Sun Nuclear aims to ease technology adoption, enhance workflows and improve outcomes – so that healthcare providers can achieve real results for Patient Safety. Learn more: Sun Nuclear, AdaptCHECK, SunCHECK, Plan AI, SunSILICON, SunSCAN 3D and evrCAM are trademarks or registered trademarks of Mirion Technologies, Inc. and/or its affiliates in the United States and/or other countries. Varian Medical Systems® is a registered trademark, and Ethos™ is a trademark, of Varian Medical Systems, Inc. Sun Nuclear Corporation is not affiliated with or sponsored by Varian Medical Systems, Inc.
Yahoo
4 hours ago
- Yahoo
EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-CoV-2 Variant LP.8.1
Moderna's updated COVID-19 mRNA vaccine will be available for the 2025-2026 vaccination season, pending a European Commission authorization decision CAMBRIDGE, MA / / July 25, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending marketing authorization for an updated formulation of the COVID-19 vaccine Spikevax®, targeting the SARS-CoV-2 variant LP.8.1, for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals six months of age and older. Following the CHMP's positive opinion, the European Commission will make a marketing authorization decision on Moderna's updated COVID-19 vaccine for the 2025-2026 season. "The CHMP's positive opinion on our updated COVID-19 vaccine targeting the SARS-CoV-2 variant LP.8.1 is an important milestone in our ongoing effort to protect people across the European Union," said Stéphane Bancel, Chief Executive Officer of Moderna. "COVID-19 continues to place a significant burden on vulnerable populations and healthcare systems. Updated vaccines can be an important tool for protecting individuals and societies." The CHMP decision is based on a combination of manufacturing and preclinical data, as well as previous clinical, non-clinical and real-world evidence supporting the efficacy and safety of Moderna's COVID-19 vaccines. The updated vaccine composition aligns with guidance from various global health authorities, which have identified the LP.8.1 strain as an appropriate update to the COVID-19 vaccine composition for the 2025-2026 vaccination season. Additional regulatory applications for Moderna's updated COVID-19 vaccines targeting LP.8.1 are under review around the world. About Moderna Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines. Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the potential authorization by the European Commission of Moderna's COVID-19 vaccine targeting the SARS-CoV-2 variant LP.8.1; and the opportunity for Moderna to sell COVID-19 vaccines to up to 17 participating European Union countries over a four-year period. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading "Risk Factors" in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC's website at Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release. Moderna Contacts Media:Clothilde CailletDirector, Country and Europe Communications Investors:Lavina TalukdarSenior Vice President & Head of Investor Relations+1 SOURCE: Moderna, Inc. View the original press release on ACCESS Newswire Sign in to access your portfolio
Miami Herald
4 hours ago
- Miami Herald
Oswaldo Muñoz, pioneer of Venezuelan community in Miami, dies after long illness
Oswaldo Muñoz, entrepreneur, editor, community leader and a key figure in the history of the Venezuelan diaspora in the United States, died on July 25 in Madrid at the age of 73 after a long battle with cancer. Founder of the community newspaper El Venezolano and later of El Venezolano TV, both based in Miami, Muñoz was a beloved and visionary figure who helped weave the first threads of unity among Venezuelans in South Florida, back when they were just beginning to arrive in the city in the early 1990s. He died as he lived: discreetly, surrounded by the love of those closest to him, and faithful to his nature of shielding others from his own suffering. 'He didn't want anyone to know what he was going through,' said Ignacio Marcano, one of his closest companions during his final days. 'He would tell people he was just getting some tests done. He never wanted to worry anyone.' After Muñoz's final hospital visit, his doctors decided to sedate him. He passed away peacefully at 7 am local time in Madrid. Pioneer in unknown territory Oswaldo arrived in Miami in 1991, at a time when the Venezuelan community was so small that, as he liked to say, 'we could all fit in a restaurant dining room.' He founded El Venezolano in August 1992, just days after the devastating impact of Hurricane Andrew on South Florida. Against all odds, he managed to distribute the first edition amid the hurricane's devastation. From then on, El Venezolano became a beacon for thousands of newly arrived Venezuelans seeking news, guidance and a voice to represent them in exile. What began as a modest entrepreneurial venture turned into an influential media outlet with franchises in other U.S. cities and across Latin America. 'Oswaldo was the Venezuelan who brought Venezuelans and the local Miami community together the most,' said José Hernández, a friend and colleague who led the editorial team at El Venezolano for years. 'He was one of the first visible leaders at a time when there were hardly any Venezuelans in the city. He shared spaces with figures like Jorge Mas Canosa and other important community leaders.' More than just a paper For years, El Venezolano served as an extension of the Venezuelan consulate, especially when the official representation ceased operating in Miami. 'On many occasions, we functioned as the consulate,' recalls Sylvia Bello, Muñoz's business partner, friend and colleague for 25 years. 'Oswaldo was a man who supported so many people in every way.' The paper became a platform for employment, integration and gathering. 'He gave work to a lot of people,' Bello said. 'He organized events that brought together hundreds. At our anniversary editions, we hosted as many as 600 people in Miami's most prestigious hotels. Those were celebrations that showcased the strength and pride of our community.' Between 1998 and the years leading up to the COVID-19 pandemic, El Venezolano was an undisputed reference point—not only for its content but also for the approachable and charismatic style of its founder. Muñoz had a natural ability to connect with public figures and celebrities, his colleagues said. 'He was friends with everyone: El Puma (José Luis Rodríguez), the Stefans (Gloria and Emilio), you name it. He wasn't afraid of anything. He'd pick up the phone and everyone would answer,' Bello recalled. Those who knew him agree that behind the editor was a deeply generous person, always ready to help. 'He was the friend everyone wants to have—unconditional, compassionate, always smiling,' Bello added. For many immigrants arriving without support networks, without jobs, and without any idea of how to begin anew in a foreign city, Oswaldo was a guide and anchor. 'There was no one who approached him for help and didn't receive it,' Hernández said. 'In a way, he helped the city grow. Many people advertised with him, and many businesses started thanks to El Venezolano.' In a story he proudly shared, Oswaldo recounted meeting Nobel-prize winning novelist Gabriel García Márquez at a book fair in Bogotá. The Colombian writer complimented his writing. Oswaldo humbly replied that he wasn't a journalist by profession. García Márquez responded: 'You're wrong. Journalism is a craft, not a profession.' Few lines could have better described Muñoz's path. Without a university degree in journalism, he built a career based on vocation, instinct, empathy and an ability to connect with people. Enduring legacy Muñoz's legacy cannot be measured solely in printed issues or TV broadcasts. His greatest contribution, those close to him said, is the community he helped build. 'He fulfilled all his dreams,' says Sylvia Bello. 'Now he's in a better place, and he left a mark on each of us who knew him.' Over the last three years, Oswaldo waged a tough battle with cancer. It started in his spine, then moved to his lungs. Later, doctors needed to remove a kidney. Despite everything, he managed to recover multiple times. 'He always had this amazing ability to bounce back. I don't know how he did it,' Bello says. 'But eventually, his body said, 'This is it.'' Despite his deteriorating health, he tried to maintain life as normal as possible, those close to him said. Muñoz leaves behind a grateful community, dozens of friends, former coworkers, readers, and partners who considered him family, his friends said. He also leaves behind a body of work that will live on through the pages of El Venezolano and in the memories of those whose lives he touched. He was, in the words of those who knew and admired him, 'the unconditional friend everyone hopes to have,' perhaps the best headline to remember his life by.
